News
-
According to SoftOx Solutions, the Danish Medicines Agency has approved the company’s application for a Phase 2a trial of SoftOx hypochlorous acid inhalation solution in healthy volunteers and in patients with cystic fibrosis. SoftOx announced… Read more . . .
-
The Chinese National Medical Products Administration (NMPA) has approved a 2 mg dose of ARS Pharmaceuticals’s neffy epinephrine nasal spray for the treatment of anaphylaxis in patients who weigh 30 kg or more, the company said.… Read more . . .
-
Cipla has launched Afrezza inhaled dry powder insulin for the treatment of diabetes in adult patients in India, the company said. Cipla acquired the rights to market Afrezza in India from MannKind Corporation in 2018,… Read more . . .
-
Once again, the annual Drug Delivery to the Lung (DDL) conference drew approximately 1,000 inhaled and nasal drug delivery experts to the Edinburgh International Conference Centre, with an additional 100 delegates attending online. With a… Read more . . .
-
According to Savara, the company has resubmitted its BLA for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) with a request for priority review. Molbreevi has been granted Breakthrough Therapy and Fast Track… Read more . . .
-
More than a year after agreeing to merge, DPI developer Pulmatrix, and biopharm Cullgen have agreed to waive a no solicitation clause included in the November 2024 merger agreement. According to the announcement, the companies… Read more . . .
-
Vistagen has announced that the Phase 3 PALISADE-3 study of intranasal fasedienol for the treatment of social anxiety disorder failed to meet its primary endpoint, with fasedienol failing to demonstrate a statistically significant reduction of… Read more . . .
-
According to Asia Scientific Global, the FDA has cleared an IND that will allow a Phase 1 trial of its Beta1 inhaled dry powder therapy for the treatment of erectile dysfunction to move forward, and… Read more . . .
-
Tiziana Life Sciences has announced the initiation of a Phase 2 trial of intranasal foralumab in patients with early-stage Alzheimer’s disease. In June 2024, Tiziana said that it had received approval for the use of… Read more . . .
-
Lee’s Pharmaceutical Holdings subsidiary Nova Pneuma has acquired inhaled drug delivery technology and other assets developed by Alexza Pharmaceuticals, the company said. Alexza merged with Grupo Ferrer in 2016. The deal, which is expected to close… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland